The Company has signed a distribution agreement that assigns to Glo-Med the role of Inspira's primary distributor and customer support center in the U.S.RA'ANANA, Israel, Oct. 24, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, is pleased to announce that it has entered into an agreement with Glo-Med Networks Inc ("Glo-Med"), which will serve as Inspira's primary distributo ...

RA'ANANA, Israel, Oct. 9, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking respiratory support technology company, is pleased to announce the development of a new disposable kit for the perfusion market. This strategic move is central to Inspira's business strategy of generating recurring revenues for products to be deployed in conjunction with the INSPIRA ART100 and that are also intended to be co ...

Inspira Technologies OXY B.H.N. Ltd. (IINN) recently announced its significant appearance at the 34th Annual Extracorporeal Life Support Organization ("ELSO") conference in Detroit, MI. The ELSO conference will take place from Sept. 29 to Sept.30, 2024. At the conference, IINN will present its latest and future technologies, highlighting the company's commitment to innovation in extracorporeal blood circulation technologies. Impact of the News on IINN Stock Following the news, shares of IINN rose 0.8% to $1 ...

RA'ANANA, Israel, Sept. 24, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW), ("Inspira Technologies", "Inspira", or the "Company") a breakthrough medical technology company, is poised to make a significant impact at the 34th Annual Extracorporeal Life Support Organization (ELSO) Conference in Detroit, Michigan, on the 29th to the 30th of September 2024. The Company will be presenting its latest and future technologies, underscoring its commitment to innovation and excellence ...

To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA™ ART device Targeting treatment for 20 million ICU patients with respiratory failure annually, with many relying on mechanical ventilators, in a $19 billion industry RA'ANANA, Israel, Sept. 13, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company targeting to supersede mechanical ventilat ...

Inspira Technologies OXY B.H.N. Ltd. (IINN) recently announced plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients. Since the medical industry is highly interested in the HYLA blood sensor, these clinical results should be on par with Inspira's long-term growth plans. About Inspira's HYLA Blood Sensor HYLA blood sensor is an advanced tubing clip-on sensor designed to monitor a patient's state in real-time by continuously measuring vital blood parameters. The clip-on ...

The clip-on HYLA™ blood sensor, designed to alert physicians of immediate signs of changes in a patient's clinical condition without the need for intermittent actual blood samples, targets a potential $2.5 billion Point of Care testing and Arterial Blood Gas (ABG) analyzer market. RA'ANANA, Israel, Aug. 28, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced plans to report clinic ...

Inspira Technologies OXY B.H.N. Ltd. (IINN) recently announced the FDA listing of its INSPIRA CART. This medical cart, designed for use with the INSPIRA ART100 system, aims to enhance healthcare delivery in operating rooms during cardiopulmonary bypass procedures. The FDA classification as a Class I Medical Device and 510(K) Exempt highlights its compliance with rigorous safety and efficacy standards, paving the way for its introduction to the U.S. market. Significance of the Announcement The FDA listing of ...

Core Viewpoint - Inspira Technologies has received FDA listing for its INSPIRA™ CART, designed to enhance the INSPIRA™ ART100 system, aiming to improve healthcare delivery in various clinical settings [1][2]. Company Overview - Inspira Technologies focuses on life-support technology innovation, targeting a combined market opportunity of approximately $59 billion annually through its advanced blood oxygenation and monitoring technologies [3]. Product Development - The INSPIRA™ CART is classified as a Class I Medical Device and is 510(K) Exempt, facilitating its entry into the U.S. market for use in cardiopulmonary bypass procedures [2][7]. - The company is developing several products, including the HYLA™ blood sensor for continuous blood parameter monitoring and the INSPIRA™ Cardi-ART, a portable unit for brain oxygenation during cardiac arrest [4][5][6]. Regulatory Status - The INSPIRA™ ART100 system has received FDA 510(k) clearance for cardiopulmonary bypass procedures and AMAR certification for extra-corporeal membrane oxygenation [7].

RA'ANANA, Israel, Aug. 13, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira," "Inspira Technologies," or the "Company"), a trailblazer in life-support technology, today announced that it was approached by a leading medical technology company in the industry, to evaluate the operation of its proprietary key product in combination with the INSPIRA™ ART100 system. The evaluation was conducted by Inspira researchers. The test results exceeded 100% of the standar ...